{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:16:56Z","timestamp":1783664216656,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple-negative breast cancer (TNBC) is characterized by high heterogeneity and poor prognosis. A particularly aggressive subset, termed \u2018rapid relapse\u2019 TNBC (rrTNBC), is defined by distant metastasis or death within 24 months of diagnosis. Understanding the unique recurrence patterns and prognostic determinants of rrTNBC is crucial for deciphering tumor evolution and optimizing therapeutic strategies. This study aims to delineate the clinicopathological features, recurrence patterns, and prognostic outcomes of rrTNBC compared to slow relapse TNBC (srTNBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 638 postoperative patients with recurrent or metastatic TNBC treated at Tianjin Medical University Cancer Institute &amp;amp; Hospital. Patients were categorized into rrTNBC (relapse \u226424 months, n = 478) and srTNBC (relapse &amp;gt;24 months, n = 160). Clinicopathological variables, recurrence sites, and survival outcomes, including disease-free survival (DFS), progression-free interval (PFI) after first salvage therapy, post-recurrence survival (PRS), and overall survival (OS), were compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to srTNBC, rrTNBC was associated with higher TNM stage, T stage, N stage, and a lower proportion of stromal tumor-infiltrating lymphocyte expression (all p &amp;lt; 0.001). Regarding recurrence patterns, rrTNBC patients were more likely to present with visceral (74.90% vs. 22.50%, p &amp;lt; 0.001) and brain metastases (10.88% vs. 0.62%, p &amp;lt; 0.001) as the first event, whereas srTNBC patients had a higher incidence of first relapse in the chest wall or regional lymph nodes (90.00% vs. 62.13%, p &amp;lt; 0.001). Consequently, rrTNBC was characterized by a significantly higher rate of direct distant metastasis at first recurrence (93.10% vs. 28.12%, p &amp;lt; 0.001). Prognostically, rrTNBC patients had markedly worse outcomes across all metrics compared to srTNBC patients, including median disease-free survival (13.4 vs. 26.6 months), median PFI after first-line salvage therapy (2.27 vs. 8.43 months), median PRS (12.1 vs. 23.5 months), and median overall survival (26.5 vs. 52.0 months) (all p &amp;lt; 0.001). In the platinum-based first-line salvage therapy subgroup (n = 369), rrTNBC patients (n = 267) consistently demonstrated significantly shorter DFS, PFI, PRS, and OS compared to srTNBC patients (n = 102) (all p &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>rrTNBC represents a distinct, highly aggressive phenotype with a predilection for visceral and brain metastasis and a dismal response to conventional platinum-based salvage therapy. These findings are consistent with the aggressive clonal evolution within rrTNBC and highlight an urgent need for novel therapeutic strategies to be prospectively evaluated in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1889398","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:21Z","timestamp":1783661901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid relapse in triple-negative breast cancer: clinical patterns, platinum resistance, and implications for clonal evolution"],"prefix":"10.3389","volume":"17","author":[{"given":"Tao","family":"Ma","sequence":"first","affiliation":[{"name":"The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital","place":["Tianjin, China"]},{"name":"Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education","place":["Tianjin, China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital","place":["Tianjin, China"]},{"name":"Key Laboratory of Cancer Immunology and Biotherapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Long","family":"Cai","sequence":"additional","affiliation":[{"name":"The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital","place":["Tianjin, China"]},{"name":"Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education","place":["Tianjin, China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital","place":["Tianjin, China"]},{"name":"Key Laboratory of Cancer Immunology and Biotherapy","place":["Tianjin, China"]},{"name":"Department of Thyroid and Breast Surgery, Comprehensive Breast Health Center, The Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People\u2019s Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Dan","family":"Chen","sequence":"additional","affiliation":[{"name":"First Department of Cadre Clinic, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital","place":["Tianjin, China"]},{"name":"Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education","place":["Tianjin, China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital","place":["Tianjin, China"]},{"name":"Key Laboratory of Cancer Immunology and Biotherapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/genes15010027","article-title":"The mutational spectrum of Pre- and post-neoadjuvant chemotherapy triple-negative breast cancers","volume":"15","author":"Aguilar-Mahecha","year":"2023","journal-title":"Genes (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.6004\/jnccn.2020.7659","article-title":"Sociodemographic factors associated with rapid relapse in triple-negative breast cancer: a multi-institution study","volume":"19","author":"Asad","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1186\/s12885-026-15928-0","article-title":"Spatial and temporal intratumoral heterogeneity in breast cancer: a systematic and conceptual review of single-cell and spatial omics studies","volume":"26","author":"Barjij","year":"2026","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3892\/ol.2026.15504","article-title":"Orchestrating organotropism: miRNA-driven mechanisms of site-specific metastasis in triple-negative breast cancer","volume":"31","author":"Bu","year":"2026","journal-title":"Oncol. Lett."},{"key":"B9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","article-title":"Pattern of metastatic spread in triple-negative breast cancer","volume":"115","author":"Dent","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-020-6668-z","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/annonc\/mdv106","article-title":"Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (definition for the assessment of time-to-event endpoints in CANcer trials)","volume":"26","author":"Gourgou-Bourgade","year":"2015","journal-title":"Ann. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(15)70064-1","article-title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Hu","year":"2015","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S2090","DOI":"10.1016\/j.jare.2025.11.038","article-title":"ZUP1 promotes DNA repair and immune evasion to drive olaparib resistance in triple-negative breast cancer","volume":"16","author":"Huang","year":"2025","journal-title":"J. Adv. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10555-022-10023-9","article-title":"Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review","volume":"41","author":"Kavan","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","article-title":"Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1245\/s10434-021-09688-3","article-title":"Socioeconomic and surgical disparities are associated with rapid relapse in patients with triple-negative breast cancer","volume":"28","author":"Obeng-Gyasi","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/annonc\/mdz395","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","volume":"30","author":"Park","year":"2019","journal-title":"Ann. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(23)00157-2","article-title":"Setting international standards in analyzing patient-reported outcomes and quality of life endpoints in cancer clinical trials-innovative medicines initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures","volume":"24","author":"Pe","year":"2023","journal-title":"Lancet Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/jnci\/djab202","article-title":"The incidence of breast cancer recurrence 10-32 years after primary diagnosis","volume":"114","author":"Pedersen","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"B32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.annonc.2020.10.475","article-title":"Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial","volume":"32","author":"Sipos","year":"2021","journal-title":"Ann. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1200\/JCO.21.01536","article-title":"Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)Adjuvant systemic therapy","volume":"40","author":"T de Jong","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1038\/s41467-022-31704-7","article-title":"A randomized phase 3 trial of gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13058-015-0665-1","article-title":"Breast cancer brain metastases: biology and new clinical perspectives","volume":"18","author":"Witzel","year":"2016","journal-title":"Breast Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-008-0096-0","article-title":"Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients","volume":"115","author":"Yin","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","article-title":"Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s12885-021-08320-7","article-title":"Genomic features of rapid versus late relapse in triple negative breast cancer","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1889398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:21Z","timestamp":1783661901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1889398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":42,"alternative-id":["10.3389\/fphar.2026.1889398"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1889398","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1889398"}}